As many as 1.3 crore shares, or 3.2% equity of Mankind Pharma worth ₹2736.8 crore changed hands on Tuesday, March 26.
The official buyers and sellers in the block deal are not yet known.
On Monday, March 25, sources told CNBC-TV18 that Beige Ltd, an affiliate of private equity firm ChrysCapital, was ikely to sell up to 2.90% of its stake in the drug firm via block deals, offering shares at a price range of ₹2,103-₹2,214.
The deal was estimated to be worth ₹2,460 crore, according to multiple people familiar with the development. Beige Ltd currently holds a 2.99% stake in Mankind Pharma Ltd. The offer price of these block deals comes at a slight discount, ranging from 0-5% below the current market price (CMP), sources told CNBC-TV18 on Monday.
Mankind Pharma made its debut on bourses on May 9, 2023, listing at ₹1,300 apiece against the issue price of ₹1,026-1,080 per share—a 20.4% premium to the issue price.
The pharmaceutical and consumer health company’s over ₹4,300 crore initial public offering (IPO) opened for subscription on April 25 and concluded on April 27.
Mankind Pharma shares were trading 1.8% lower at ₹2,173.95 apiece at 9.25 am
